ERBB2 and breast cancer: This finding suggests that the frequency of PIK3CA mutation in HER2+ BC may be underestimated by archival tissue evaluation, proposing liquid biopsy as a useful tool to better capture temporal heterogeneity, thus potentially expanding the proportion of patients that could benefit from targeted therapy [Table 1].